ST Renfu announced that Jiulong Renfu, a holding subsidiary of the company, recently received the “Drug Registration Certificate” for resorcinol tablets approved and issued by the State Drug Administration. The drug is a class 3 chemical with a specification of 80 mg to treat acute spasmodic pain, acute spasmodic urethral/bladder/renal colic, and gynecological spasmodic pain caused by digestive system and biliary dysfunction. Jiulong Renfu is the marketing license holder and has commissioned Nanjing Haina Pharmaceutical for production. Up to now, it has invested about 8 million yuan. The product has been approved to enrich the company's product line, and there is uncertainty about future sales.

ST Renfu announced that Jiulong Renfu, a holding subsidiary of the company, recently received the “Drug Registration Certificate” for resorcinol tablets approved and issued by the State Drug Administration. The drug is a class 3 chemical with a specification of 80 mg to treat acute spasmodic pain, acute spasmodic urethral/bladder/renal colic, and gynecological spasmodic pain caused by digestive system and biliary dysfunction. Jiulong Renfu is the marketing license holder and has commissioned Nanjing Haina Pharmaceutical for production. Up to now, it has invested about 8 million yuan. The product has been approved to enrich the company's product line, and there is uncertainty about future sales.